Autopsy report · NCT04754334

A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

Cause of deathFutility Automatic label, confidence 0.5, unverified. How labels are made.

“The ORA-D-013-2 protocol was terminated based on the primary results analyzed at week 26 in the ORA-D-013-1 protocol.”

The sponsor’s own words in the registry.

Life of this trial

Registered 1 month before it started.
Ran for about 1 year 10 months before it stopped.
346 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: Oramed, Ltd.
Sponsor type: Industry
Conditions: T2DM (Type 2 Diabetes Mellitus)
Interventions: ORMD-0801; Placebo
Participants: 346
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.